ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
IDWeek 2023: Shionogi Presents New Real-World Evidence Demonstrating Effectiveness of Earlier Treatment with Fetroja® (cefiderocol) in Appropriate Patients
ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens
Shionogi’s Antibiotic, FETCROJA® (cefiderocol), Is Now Available in the Netherlands
Shionogi’s Innovative Antibiotic, FETCROJA® (cefiderocol), Is Now Available in Denmark
Shionogi’s Innovative Antibiotic, FETCROJA® (cefiderocol), Is Now Available in Norway
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., announced that new Fetroja® (cefiderocol) data will be presented at IDWeek 2022 including new real-world evidence demonstrating Fetroja’s strong efficacy against some of the most difficult-to-treat Gram-negative bacterial infections.
Shionogi’s novel antibiotic Fetcroja (cefiderocol) has been selected by the UK’s National Institute for Health and Care Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) to be included in a pilot subscription reimbursement model.
Shionogi’s novel antibiotic Fetcroja (cefiderocol) has been selected by the UK’s National Institute for Health and Care Excellence (NICE) and the National Health Service England and Improvement (NHSE&I) to be included in a pilot subscription reimbursement model.
Japanese pharmaceutical company Shionogi today announced that NICE and NHS England and Improvement (NHSE&I) have selected its novel antibiotic Fetcroja (cefiderocol) for inclusion in a pilot subscription reimbursement model in the UK, which ‘de-links’ payment from volume of use.